Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S. Placke T, et al. Among authors: sykes sm. Blood. 2014 Jul 3;124(1):13-23. doi: 10.1182/blood-2014-02-558114. Epub 2014 Apr 24. Blood. 2014. PMID: 24764564 Free PMC article.
The identity crisis of Hif-1α in HSC biology.
Sykes SM. Sykes SM. Blood. 2016 Jun 9;127(23):2782-4. doi: 10.1182/blood-2016-04-710459. Blood. 2016. PMID: 27282941 Free article. No abstract available.
MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.
Maifrede S, Martinez E, Nieborowska-Skorska M, Di Marcantonio D, Hulse M, Le BV, Zhao H, Piwocka K, Tempera I, Sykes SM, Skorski T. Maifrede S, et al. Among authors: sykes sm. Blood Adv. 2017 Aug 9;1(19):1467-1472. doi: 10.1182/bloodadvances.2017006247. eCollection 2017 Aug 22. Blood Adv. 2017. PMID: 29296788 Free PMC article.
RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Marcantonio DD, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S, Scholl C. Rudat S, et al. Among authors: sykes sm. Leukemia. 2018 Oct;32(10):2189-2202. doi: 10.1038/s41375-018-0102-4. Epub 2018 Mar 22. Leukemia. 2018. PMID: 29654265
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T. Maifrede S, et al. Among authors: sykes sm. Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21. Blood. 2018. PMID: 29784639 Free PMC article.
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Nacson J, Krais JJ, Bernhardy AJ, Clausen E, Feng W, Wang Y, Nicolas E, Cai KQ, Tricarico R, Hua X, DiMarcantonio D, Martinez E, Zong D, Handorf EA, Bellacosa A, Testa JR, Nussenzweig A, Gupta GP, Sykes SM, Johnson N. Nacson J, et al. Among authors: sykes sm. Cell Rep. 2018 Sep 25;24(13):3513-3527.e7. doi: 10.1016/j.celrep.2018.08.086. Cell Rep. 2018. PMID: 30257212 Free PMC article.
71 results